This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Applied Genetic Technologies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

92.6%

Borç/özkaynak oranı

US$16.34m

Borç

Faiz karşılama oranı	n/a
Nakit	US$34.24m
Eşitlik	US$17.65m
Toplam yükümlülükler	US$39.69m
Toplam varlıklar	US$57.33m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 2GT's short term assets ($37.2M) exceed its short term liabilities ($26.6M).

Uzun Vadeli Yükümlülükler: 2GT's short term assets ($37.2M) exceed its long term liabilities ($13.1M).

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 2GT has more cash than its total debt.

Borcun Azaltılması: Insufficient data to determine if 2GT's debt to equity ratio has reduced over the past 5 years.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 2GT has less than a year of cash runway based on its current free cash flow.

Tahmini Nakit Akışı: 2GT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 15.4% each year

This company listing is no longer active

Applied Genetic Technologies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Applied Genetic Technologies Corporation announced delayed 10-Q filing

Applied Genetic Technologies Receives Non-Compliance Notice from Nasdaq

Recent updates

Applied Genetic Technologies Corporation(NasdaqGM:AGTC) dropped from NASDAQ Composite Index

Syncona Limited (LSE:SYNC), a fund managed by Syncona Investment Management Limited completed the acquisition of Applied Genetic Technologies Corporation (NasdaqGM:AGTC).

Applied Genetic Technologies Corporation announced delayed 10-Q filing

Insufficient new directors

Syncona Limited (LSE:SYNC), a fund managed by Syncona Investment Management Limited, entered into a definitive agreement to acquire Applied Genetic Technologies Corporation (NasdaqGM:AGTC) for $23.3 million.

Applied Genetic Technologies Corporation has completed a Follow-on Equity Offering.

Applied Genetic Technologies Corporation has completed a Follow-on Equity Offering.

Applied Genetic Technologies Receives Non-Compliance Notice from Nasdaq

Applied Genetic Technologies Corporation Announces Executive Appointments

AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa

Applied Genetic Technologies Corporation Presents Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 At the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

Insufficient new directors

Insufficient new directors

Ivana Magovcevic-Liebisch Resigns from Board of Directors and Each Committee of Which She Was A Member of Applied Genetic Technologies Corporation, Effective March 9, 2022

Insufficient new directors

Applied Genetic Technologies Reports Updated Interim Three-Month Pediatric Results and Additional Adult Safety Results Out to as Long as 24 Months from Its Ongoing Phase 1/2 Dose Escalation Study of AGTC-401

Applied Genetic Technologies Corporation to Report Q2, 2022 Results on Feb 14, 2022

AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Insufficient new directors

Insufficient new directors

Applied Genetic Technologies Corporation Announces Ongoing Clinical Trials in achromatopsia and X-Linked Retinitis Pigmentosa at the Fourteenth International Symposium on Retinal Degeneration

Applied Genetic Technologies Corporation(NasdaqGM:AGTC) dropped from Russell 3000E Index

Applied Genetic Technologies Corporation Reports 12-Month Data from Its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene

Otonomy, Inc. and Applied Genetic Technologies Corporation Present Preclinical Proof-Of-Concept Results for Oto-825 Gene Therapy At ASGCT Annual Meeting

Applied Genetic Technologies Corporation Advances for Manufacturing its XLRP Gene Therapy Candidate in Two Abstracts at ASGCT

Applied Genetic Technologies Corporation Reports Additional Positive Data from the Ongoing X-Linked Retinitis Pigmentosa Phase 1/2 Clinical Trial

Agtc Clinical Investigators Provide Encore Presentation of Data from the Company’s Ongoing XLRP and Achromatopsia Phase 1/2 Trials

Revenue in line with expectations

Applied Genetic Technologies Corporation to Report Q2, 2021 Results on Feb 11, 2021

New 90-day low: €3.20

Applied Genetic Technologies Corporation has completed a Follow-on Equity Offering in the amount of $74.5 million.

New 90-day low: €3.30

New 90-day low: €3.94

Revenue in line with expectations

Applied Genetic Technologies Corporation Reports Additional Positive Data from its Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosa

Applied Genetic Technologies Corporation Plans to Release 12-Month Data for Groups 1 Through 4 Evaluating Durability of Effect and Continued Safety and Interim Data of Groups 5 and 6 Evaluating Safety and Efficacy at Higher Doses for its Phase 1/2 Clinical Trial

Applied Genetic Technologies Corporation, Annual General Meeting, Dec 16, 2020

Applied Genetic Technologies Corporation Joins the My Retina Tracker® Program as A New Scientific Collaborator

New 90-day low: €4.14

Full year earnings released - €2.17 loss per share

Applied Genetic Technologies Corporation to Report Q4, 2020 Results on Sep 09, 2020

New 90-day low - €4.16

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin